DBVT: Gunggung utang perusahaan DBV Technologies SA

The market trend for DBV Technologies S.A. (DBVT) debt on the GURU.Markets platform is fixed at 0.02. DBV Technologies S.A. relies on American and French R&D centers that develop advanced transdermal systems to combat food allergies. The business is currently revising its clinical testing plan for peanut allergy patches to align new parameters with regulatory authorities and resume commercial expansion.

This indicator reflects the total volume of borrowed funds, determining the overall financial burden on the issuer's capital. The metric aggregates all short-term and long-term liabilities to assess the business's leverage. The dynamics of debt obligations allow for tracking the company's dependence on external financing. For DBV Technologies S.A. (DBVT), which is currently in the clinical testing stage, debt growth is critical in the absence of stable revenue. Monitoring this indicator helps assess the risk of bankruptcy prior to receiving regulatory approvals.